Regulus Therapeutics Company Profile (NASDAQ:RGLS)

About Regulus Therapeutics

Regulus Therapeutics logoRegulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: RGLS
  • CUSIP: 75915K10
Key Metrics:
  • Previous Close: $3.24
  • 50 Day Moving Average: $3.51
  • 200 Day Moving Average: $5.46
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.17
  • P/E Growth: -0.05
  • Market Cap: $171.14M
  • Outstanding Shares: 52,820,000
  • Beta: 1.91
Additional Links:
Companies Related to Regulus Therapeutics:

Analyst Ratings

Consensus Ratings for Regulus Therapeutics (NASDAQ:RGLS) (?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $10.00 (208.64% upside)

Analysts' Ratings History for Regulus Therapeutics (NASDAQ:RGLS)
DateFirmActionRatingPrice TargetDetails
8/4/2016Needham & Company LLCReiterated RatingBuy$10.00View Rating Details
8/3/2016WedbushReiterated RatingOutperform$15.00View Rating Details
7/31/2016Wells Fargo & Co.Reiterated RatingOutperformView Rating Details
7/25/2016Chardan CapitalLower Price TargetBuy$14.50 -> $12.00View Rating Details
6/28/2016FBR & CoReiterated RatingOutperform$30.00 -> $9.00View Rating Details
6/28/2016BMO Capital MarketsDowngradeOutperform -> Market Perform$16.00 -> $4.00View Rating Details
6/8/2016Cowen and CompanyReiterated RatingBuyView Rating Details
6/8/2015GuggenheimInitiated CoverageBuy$16.00View Rating Details
6/2/2015Deutsche Bank AGSet Price TargetBuy$27.00View Rating Details
(Data available from 8/29/2014 forward)


Earnings History for Regulus Therapeutics (NASDAQ:RGLS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2016Q216($0.38)($0.40)$2.49 millionViewListenView Earnings Details
5/2/2016Q1($0.33)($0.40)ViewListenView Earnings Details
2/22/2016Q415($0.25)($0.14)$5.09 million$10.90 millionViewListenView Earnings Details
11/5/2015Q315($0.37)($0.25)$2.85 millionViewN/AView Earnings Details
8/4/2015Q215($0.29)($0.41)$2.40 million$3.80 millionViewN/AView Earnings Details
5/7/2015($0.26)($0.25)ViewListenView Earnings Details
2/18/2015($0.21)($0.47)ViewListenView Earnings Details
11/5/2014($0.23)($0.23)ViewListenView Earnings Details
8/6/2014Q214($0.19)($0.29)$3.19 millionViewN/AView Earnings Details
5/8/2014($0.14)($0.30)ViewN/AView Earnings Details
2/27/2014($0.13)($0.11)ViewN/AView Earnings Details
8/13/20132Q13($0.14)($0.20)$3.44 million$4.80 millionViewN/AView Earnings Details
2/20/2013Q412($0.08)($0.22)$3.50 million$3.24 millionViewN/AView Earnings Details
11/19/2012Q312($15.98)$3.81 million$2.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Regulus Therapeutics (NASDAQ:RGLS)
Current Year EPS Consensus Estimate: $-1.55 EPS
Next Year EPS Consensus Estimate: $-1.49 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.33)($0.32)($0.33)
Q2 20162($0.42)($0.32)($0.37)
Q3 20162($0.44)($0.36)($0.40)
Q4 20162($0.45)($0.35)($0.40)
Q1 20171($0.35)($0.35)($0.35)
Q2 20171($0.35)($0.35)($0.35)
Q3 20171($0.35)($0.35)($0.35)
Q4 20171($0.35)($0.35)($0.35)
(Data provided by Zacks Investment Research)


Dividend History for Regulus Therapeutics (NASDAQ:RGLS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Regulus Therapeutics (NASDAQ:RGLS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/3/2016Joseph P HaganCOOBuy10,000$7.19$71,900.00View SEC Filing  
2/23/2016Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,000,000$7.18$7,180,000.00View SEC Filing  
7/21/2015William H RastetterDirectorBuy100,000$10.17$1,017,000.00View SEC Filing  
7/20/2015William H RastetterDirectorBuy38,765$10.13$392,689.45View SEC Filing  
7/17/2015Isis Pharmaceuticals IncMajor ShareholderSell343,133$10.60$3,637,209.80View SEC Filing  
4/21/2015Kleanthis G XanthopoulosCEOSell200,000$17.15$3,430,000.00View SEC Filing  
4/13/2015Bruce L A CarterDirectorSell20,000$17.66$353,200.00View SEC Filing  
3/5/2015Kleanthis G XanthopoulosCEOSell89,230$20.26$1,807,799.80View SEC Filing  
2/2/2015Kleanthis G XanthopoulosCEOSell5,700$19.61$111,777.00View SEC Filing  
1/29/2015Kleanthis G XanthopoulosCEOSell145,000$18.06$2,618,700.00View SEC Filing  
1/28/2015Neil W GibsonInsiderSell80,000$18.05$1,444,000.00View SEC Filing  
11/28/2014Neil W GibsonInsiderSell2,500$19.30$48,250.00View SEC Filing  
11/3/2014Isis Pharmaceuticals IncMajor ShareholderSell1,279,411$15.94$20,393,811.34View SEC Filing  
10/24/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell113,084$14.02$1,585,437.68View SEC Filing  
10/22/2014Neil W GibsonInsiderSell3,300$14.44$47,652.00View SEC Filing  
10/10/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,000$6.41$12,820.00View SEC Filing  
10/10/2014Isis Pharmaceuticals IncDirectorSell10,050$6.56$65,928.00View SEC Filing  
10/9/2014Isis Pharmaceuticals IncDirectorSell4,750$6.58$31,255.00View SEC Filing  
10/8/2014Isis Pharmaceuticals IncDirectorSell3,300$6.63$21,879.00View SEC Filing  
10/3/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell10,300$6.74$69,422.00View SEC Filing  
10/3/2014Isis Pharmaceuticals IncDirectorSell3,300$6.88$22,704.00View SEC Filing  
10/2/2014Isis Pharmaceuticals IncDirectorSell3,750$6.64$24,900.00View SEC Filing  
10/1/2014Isis Pharmaceuticals IncDirectorSell3,250$6.71$21,807.50View SEC Filing  
9/30/2014Kleanthis G XanthopoulosCEOSell2,300$7.02$16,146.00View SEC Filing  
9/26/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$7.04$17,600.00View SEC Filing  
9/26/2014Isis Pharmaceuticals IncDirectorSell8,750$7.13$62,387.50View SEC Filing  
9/25/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$7.12$17,800.00View SEC Filing  
9/24/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell3,750$7.19$26,962.50View SEC Filing  
9/19/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell7,700$7.31$56,287.00View SEC Filing  
9/19/2014Isis Pharmaceuticals IncDirectorSell4,100$7.22$29,602.00View SEC Filing  
9/18/2014Isis Pharmaceuticals IncDirectorSell1,500$7.40$11,100.00View SEC Filing  
9/17/2014Isis Pharmaceuticals IncDirectorSell2,100$7.43$15,603.00View SEC Filing  
9/12/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell8,900$7.85$69,865.00View SEC Filing  
9/12/2014Isis Pharmaceuticals IncDirectorSell3,500$7.96$27,860.00View SEC Filing  
9/12/2014Neil W GibsonInsiderSell4,200$8.01$33,642.00View SEC Filing  
9/11/2014Isis Pharmaceuticals IncDirectorSell3,400$7.83$26,622.00View SEC Filing  
9/10/2014Isis Pharmaceuticals IncDirectorSell2,000$7.70$15,400.00View SEC Filing  
9/5/2014Isis Pharmaceuticals IncDirectorSell10,050$7.07$71,053.50View SEC Filing  
8/29/2014Isis Pharmaceuticals IncDirectorSell1,500$6.84$10,260.00View SEC Filing  
8/28/2014Isis Pharmaceuticals IncDirectorSell2,000$6.96$13,920.00View SEC Filing  
8/28/2014Kleanthis G XanthopoulosCEOSell3,505$7.06$24,745.30View SEC Filing  
8/27/2014Isis Pharmaceuticals IncDirectorSell1,500$7.21$10,815.00View SEC Filing  
8/22/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell5,250$6.75$35,437.50View SEC Filing  
8/21/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$6.89$17,225.00View SEC Filing  
8/20/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell3,000$7.14$21,420.00View SEC Filing  
8/15/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,450$6.98$10,121.00View SEC Filing  
8/14/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,750$7.04$12,320.00View SEC Filing  
8/13/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,250$7.02$15,795.00View SEC Filing  
8/8/2014Isis Pharmaceuticals IncDirectorSell1,850$6.80$12,580.00View SEC Filing  
8/7/2014Isis Pharmaceuticals IncDirectorSell2,600$6.66$17,316.00View SEC Filing  
8/6/2014Isis Pharmaceuticals IncDirectorSell3,150$7.08$22,302.00View SEC Filing  
8/1/2014Isis Pharmaceuticals IncDirectorSell2,600$6.21$16,146.00View SEC Filing  
7/31/2014Isis Pharmaceuticals IncDirectorSell1,750$6.42$11,235.00View SEC Filing  
7/30/2014Isis Pharmaceuticals IncDirectorSell1,000$6.60$6,600.00View SEC Filing  
7/25/2014Isis Pharmaceuticals IncDirectorSell1,700$6.55$11,135.00View SEC Filing  
7/24/2014Isis Pharmaceuticals IncDirectorSell1,850$6.81$12,598.50View SEC Filing  
7/23/2014Isis Pharmaceuticals IncDirectorSell1,700$6.88$11,696.00View SEC Filing  
7/18/2014Isis Pharmaceuticals IncDirectorSell5,000$6.80$34,000.00View SEC Filing  
7/17/2014Isis Pharmaceuticals IncDirectorSell5,000$6.58$32,900.00View SEC Filing  
7/16/2014Isis Pharmaceuticals IncDirectorSell3,500$6.59$23,065.00View SEC Filing  
7/11/2014Isis Pharmaceuticals IncDirectorSell1,750$6.48$11,340.00View SEC Filing  
7/10/2014Isis Pharmaceuticals IncDirectorSell4,500$6.69$30,105.00View SEC Filing  
7/9/2014Isis Pharmaceuticals IncDirectorSell1,800$7.08$12,744.00View SEC Filing  
2/4/2014Sanofimajor shareholderBuy1,303,780$7.67$9,999,992.60View SEC Filing  
1/21/2014Neil GibsonInsiderSell4,421$8.09$35,765.89View SEC Filing  
1/17/2014Neil GibsonInsiderSell4,479$8.15$36,503.85View SEC Filing  
1/16/2014Neil GibsonInsiderSell1,100$8.03$8,833.00View SEC Filing  
1/2/2014Kleanthis XanthopoulosCEOSell3,505$7.25$25,411.25View SEC Filing  
10/10/2012Stanley T CrookeDirectorBuy750,000$4.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Regulus Therapeutics (NASDAQ:RGLS)
DateHeadline logoCan Regulus Therapeutics Inc. (NASDAQ:RGLS) Meet Analysts Expectations? - Stocks Daily (NASDAQ:RGLS) - August 22 at 11:43 AM logoWill Regulus Therapeutics Inc. (NASDAQ:RGLS) Hit $15 Price Target? - Investor Newswire (NASDAQ:RGLS) - August 18 at 7:24 PM logoWill Regulus Therapeutics Inc. (NASDAQ:RGLS) Surprise Analysts? - Investor Newswire (NASDAQ:RGLS) - August 14 at 11:33 AM logoREGULUS THERAPEUTICS INC. Financials (NASDAQ:RGLS) - August 10 at 7:38 PM logoRegulus Therapeutics Inc.: Regulus to Present at the 2016 Wedbush PacGrow Healthcare Conference (NASDAQ:RGLS) - August 9 at 7:24 PM logoRegulus to Present at the 2016 Wedbush PacGrow Healthcare Conference (NASDAQ:RGLS) - August 9 at 7:24 PM logoETF’s with exposure to Regulus Therapeutics, Inc. : August 8, 2016 (NASDAQ:RGLS) - August 8 at 7:20 PM logoRegulus Therapeutics, Inc. :RGLS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016 (NASDAQ:RGLS) - August 5 at 7:21 PM logoRegulus Therapeutics Inc. (RGLS) Jumps 6.8% on August 03 - (NASDAQ:RGLS) - August 5 at 10:07 AM
News IconHC Stocks in Actions: Pernix Therapeutics Holdings Inc (NASDAQ:PTX), Regulus Therapeutics Inc (NASDAQ:RGLS) - share market updates (press release) (NASDAQ:RGLS) - August 4 at 7:36 PM logoStrong Sell Calls For Regulus Therapeutics Inc. (NASDAQ:RGLS) At 0 - Investor Newswire (NASDAQ:RGLS) - August 4 at 7:36 PM logoEdited Transcript of RGLS earnings conference call or presentation 2-Aug-16 9:00pm GMT (NASDAQ:RGLS) - August 3 at 10:23 AM logoREGULUS THERAPEUTICS INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:RGLS) - August 3 at 10:23 AM logoRegulus Reports Second Quarter 2016 Financial Results (NASDAQ:RGLS) - August 2 at 7:27 PM logoRegulus reports 2Q loss (NASDAQ:RGLS) - August 2 at 7:27 PM logoQ2 2016 Regulus Therapeutics Inc Earnings Release - After Market Close (NASDAQ:RGLS) - August 2 at 12:04 PM logoRegulus Therapeutics Inc Earnings Call scheduled for 5:00 pm ET today (NASDAQ:RGLS) - August 2 at 12:04 PM logoMarket Update – Biggest Movers Pre Market (NASDAQ:RGLS) - August 1 at 11:47 AM logoRegulus Therapeutics Inc. (RGLS) Drops 13.05% on July 28 - (NASDAQ:RGLS) - July 31 at 11:02 AM
News IconAnalyst Recommended Stock: Anavex Life Sciences Corp. (AVXL) (NASDAQ:RGLS) - July 29 at 7:18 PM logoWells Fargo Reacts To Regulus News Of FDA Request For Info Regarding Clinical Hold (NASDAQ:RGLS) - July 29 at 10:09 AM
News IconBiotech Gainers Grab Market Attentions- BioMarin Pharmaceutical (NASDAQ:BMRN), Regulus Therapeutics (NASDAQ ... - Seneca Globe (NASDAQ:RGLS) - July 28 at 7:23 PM
News IconHC Stocks in Drift: Pernix Therapeutics Holdings Inc (NASDAQ:PTX), Regulus Therapeutics Inc (NASDAQ:RGLS) - share market updates (press release) (NASDAQ:RGLS) - July 28 at 7:23 PM logoRegulus Therapeutics (RGLS) Provided Update on Clinical Hold of RG-101; Anticipates Submitting Necessary Info by ... - (NASDAQ:RGLS) - July 28 at 7:23 PM logoBiotech Ready for a Breakout (NASDAQ:RGLS) - July 28 at 10:23 AM logoRegulus Therapeutics : Provides Update on Clinical Hold of RG-101 (NASDAQ:RGLS) - July 28 at 10:23 AM logoRegulus Therapeutics (RGLS) Provided Update on Clinical Hold of RG-101; Anticipates Submitting Necessary Info by Early Q4 (NASDAQ:RGLS) - July 28 at 10:23 AM logoRegulus Provides Update on Clinical Hold of RG-101 (NASDAQ:RGLS) - July 27 at 4:28 PM logo4:14 pm Regulus Therapeutics announces that, as anticipated, it received written communication from the FDA outlining information required to resolve the clinical hold for its IND for RG-101 (NASDAQ:RGLS) - July 27 at 4:14 PM
News IconHC Stocks in Focus: Regulus Therapeutics Inc (NASDAQ:RGLS), Allergan plc Ordinary Shares (NYSE:AGN) - share market updates (press release) (NASDAQ:RGLS) - July 27 at 10:10 AM logoRegulus to Release Second Quarter Financial Results on August 2, 2016 (NASDAQ:RGLS) - July 26 at 4:48 PM
News IconIs Buying Regulus Therapeutics Inc Here a Winning Strategy? - Press Telegraph (NASDAQ:RGLS) - July 22 at 10:03 AM
News IconRegulus Therapeutics Inc. (NASDAQ:RGLS): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:RGLS) - July 22 at 10:03 AM logoRegulus Therapeutics Inc. (RGLS) Jumps 5.28% on July 20 - (NASDAQ:RGLS) - July 22 at 10:03 AM
News IconHC Stocks Indications: Regulus Therapeutics Inc (NASDAQ:RGLS), Allergan plc Ordinary Shares (NYSE:AGN) - share market updates (press release) (NASDAQ:RGLS) - July 20 at 7:59 PM logoRegulus Therapeutics Inc. (RGLS) Drops 7.2% on July 19 - (NASDAQ:RGLS) - July 20 at 7:59 PM
News IconNotable Stock's Buzzers: Comcast Corporation (NASDAQ:CMCSA), Regulus Therapeutics Inc (NASDAQ:RGLS) - NYSE Journal (press release) (NASDAQ:RGLS) - July 19 at 8:05 AM logoRegulus Therapeutics Inc. (RGLS) Updated Price Targets - FTSE News (NASDAQ:RGLS) - July 19 at 8:05 AM logoRegulus Therapeutics Inc. (RGLS) Jumps 6.6% on July 15 - (NASDAQ:RGLS) - July 15 at 6:07 PM
News IconInvestor News: Investigation of Regulus Therapeutics Inc (NASDAQ:RGLS) over potential Violations of Securities Laws - GroundReport (NASDAQ:RGLS) - July 14 at 7:22 PM
News IconHow Analysts Feel About Regulus Therapeutics Inc (NASDAQ:RGLS)? - Consumer Eagle (NASDAQ:RGLS) - July 14 at 7:22 PM
News IconInvestor News: Investigation of Regulus Therapeutics Inc (NASDAQ:RGLS) over potential Violations of Securities Laws (NASDAQ:RGLS) - July 14 at 10:44 AM
News IconRegulus Therapeutics Incorporated (NASDAQ:RGLS) Sellers Increased By 1.49% Their Shorts - Consumer Eagle (NASDAQ:RGLS) - July 12 at 11:30 AM logoBroker Outlook For Regulus Therapeutics Inc. (RGLS) - Fiscal Standard (NASDAQ:RGLS) - July 10 at 6:22 PM logoNext Weeks Broker Price Targets For Regulus Therapeutics Inc. (RGLS) - Fiscal Standard (NASDAQ:RGLS) - July 10 at 6:22 PM logoRegulus Therapeutics Inc. Stock Momentum Hits Extreme Weakness - CML News (NASDAQ:RGLS) - July 7 at 7:12 PM logoRegulus Therapeutics Inc. (RGLS) Jumps 7.74% on July 06 - (NASDAQ:RGLS) - July 7 at 7:12 PM logoInvestor Investigation of Regulus Therapeutics Inc (NASDAQ:RGLS) over Potential Violations of Securities Laws (NASDAQ:RGLS) - July 7 at 9:54 AM
News IconHC Stocks Buzzer: Regulus Therapeutics Inc (NASDAQ:RGLS), Shire PLC (ADR) (NASDAQ:SHPG) - share market updates (press release) (NASDAQ:RGLS) - July 6 at 7:25 PM logoRegulus Therapeutics Inc. (RGLS) is Trading Higher on Unusual Volume for July 04 - (NASDAQ:RGLS) - July 6 at 7:25 PM


Regulus Therapeutics (NASDAQ:RGLS) Chart for Monday, August, 29, 2016

Last Updated on 8/29/2016 by Staff